{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:49:11Z","timestamp":1792144151774,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005616","name":"Allergan, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chicago Center for Vision Research"},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.ajo.2010.09.026","type":"journal-article","created":{"date-parts":[[2011,1,23]],"date-time":"2011-01-23T04:18:59Z","timestamp":1295756339000},"page":"671-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":327,"title":["A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study"],"prefix":"10.1016","volume":"151","author":[{"given":"Theodore","family":"Krupin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Liebmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2010.09.026_bib1","first-page":"741","article-title":"Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons","volume":"41","author":"Kerrigan-Baumrind","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9422","key":"10.1016\/j.ajo.2010.09.026_bib2","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2010.09.026_bib3","series-title":"The Glaucomas","first-page":"769","article-title":"Normal-tension glaucoma","author":"Werner","year":"1996"},{"issue":"8","key":"10.1016\/j.ajo.2010.09.026_bib4","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archopht.1991.01080080050026","article-title":"Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans","volume":"109","author":"Sommer","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2010.09.026_bib5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(92)31774-9","article-title":"Prevalence of glaucoma","volume":"99","author":"Klein","year":"1992","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2010.09.026_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2010.09.026_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2010.09.026_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS). 7: The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2010.09.026_bib9","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2010.09.026_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2010.09.026_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2010.09.026_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","article-title":"Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: An evidence-based review","volume":"127","author":"Saylor","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2010.09.026_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","article-title":"Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients","volume":"127","author":"Katz","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2010.09.026_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0149-2918(00)87981-3","article-title":"Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results","volume":"22","author":"Melamed","year":"2000","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.ajo.2010.09.026_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ophtha.2004.10.034","article-title":"The Low-pressure Glaucoma Treatment Study (LoGTS): study design and baseline characteristics of enrolled patients","volume":"112","author":"Krupin","year":"2005","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2010.09.026_bib16","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","article-title":"Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension","volume":"105","author":"LeBlanc","year":"1998","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2010.09.026_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/bjo.75.8.493","article-title":"Regression analysis of visual field progression in low tension glaucoma","volume":"75","author":"Noureddin","year":"1991","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2010.09.026_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archopht.117.9.1137","article-title":"Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment","volume":"117","author":"Katz","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2010.09.026_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0420.1997.tb00121.x","article-title":"Perimetric probability maps to separate change caused by glaucoma from that caused by cataract","volume":"75","author":"Bengtsson","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"issue":"11","key":"10.1016\/j.ajo.2010.09.026_bib20","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0161-6420(99)90497-9","article-title":"Early Manifest Glaucoma Trial: design and baseline data","volume":"106","author":"Leske","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2010.09.026_bib21","first-page":"1400","article-title":"Examination of different pointwise linear regression methods for determining visual field progression","volume":"43","author":"Gardiner","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2010.09.026_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0042-6989(03)00474-7","article-title":"Reducing noise in suspected glaucomatous visual fields by using a new spatial filter","volume":"44","author":"Gardiner","year":"2004","journal-title":"Vision Res"},{"issue":"1","key":"10.1016\/j.ajo.2010.09.026_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"7","key":"10.1016\/j.ajo.2010.09.026_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archopht.1997.01100160017002","article-title":"A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension","volume":"115","author":"Schuman","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2010.09.026_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bjo.87.6.726","article-title":"Interobserver agreement on visual field progression in glaucoma: a comparison of methods","volume":"87","author":"Viswanathan","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2010.09.026_bib26","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1167\/iovs.05-1584","article-title":"Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement","volume":"47","author":"Strouthidis","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2010.09.026_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2010.09.026_bib28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ophtha.2009.06.042","article-title":"Natural history of open-angle glaucoma","volume":"116","author":"Heijl","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2010.09.026_bib29","first-page":"1315","article-title":"Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep","volume":"26","author":"Topper","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2010.09.026_bib30","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","article-title":"Effects of brimonidine on aqueous humor dynamics in human eyes","volume":"113","author":"Toris","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2010.09.026_bib31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archopht.1995.01100070092031","article-title":"Risk factors for open-angle glaucoma: the Barbados Eye Study","volume":"113","author":"Leske","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2010.09.026_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archopht.1995.01100020100038","article-title":"Hypertension, perfusion pressure, and primary open-angle glaucoma","volume":"113","author":"Tielsch","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2010.09.026_bib33","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0161-6420(00)00138-X","article-title":"Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study","volume":"107","author":"Bonomi","year":"2000","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2010.09.026_bib34","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/archopht.119.12.1819","article-title":"The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER","volume":"119","author":"Quigley","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2010.09.026_bib35","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","article-title":"Predictors of long-term progression in the Early Manifest Glaucoma Trial","volume":"114","author":"Leske","year":"2007","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2010.09.026_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archopht.1995.01100010079024","article-title":"The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine","volume":"113","author":"Nordlund","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2010.09.026_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0002-9394(99)00160-9","article-title":"Beta-blocker eyedrops and nocturnal arterial hypotension","volume":"128","author":"Hayreh","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2010.09.026_bib38","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1167\/iovs.05-1253","article-title":"Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma","volume":"47","author":"Quaranta","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"10.1016\/j.ajo.2010.09.026_bib39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajo.2010.09.026_bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajo.2010.09.026_bib41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00415-005-0933-6","article-title":"Why have neuro-protectants failed?: lessons learned from stroke trials","volume":"252","author":"Muir","year":"2005","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.ajo.2010.09.026_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ajo.2009.03.029","article-title":"Neuroprotection: Extrapolating from neurologic diseases to the eye","volume":"148","author":"Danesh-Meyer","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2010.09.026_bib43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/archopht.117.11.1540","article-title":"Is neuroprotection a viable therapy for glaucoma?","volume":"117","author":"Weinreb","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2010.09.026_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00055735-200204000-00002","article-title":"Current understanding of neuroprotection in glaucoma","volume":"13","author":"Wein","year":"2002","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2010.09.026_bib45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archopht.1997.01100160201010","article-title":"TUNEL-positive ganglion cells in human primary open-angle glaucoma","volume":"115","author":"Kerrigan","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2010.09.026_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00000542-199308000-00016","article-title":"Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia","volume":"79","author":"Maier","year":"1993","journal-title":"Anesthesiology"},{"issue":"suppl 1","key":"10.1016\/j.ajo.2010.09.026_bib48","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1177\/112067219900901S09","article-title":"From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury","volume":"9","author":"Wheeler","year":"1999","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2010.09.026_bib49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1017\/S0952523807070605","article-title":"Localization of alpha 2 receptors in ocular tissues","volume":"24","author":"WoldeMussie","year":"2007","journal-title":"Vis Neurosci"},{"issue":"4","key":"10.1016\/j.ajo.2010.09.026_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000267170","article-title":"Localization of alpha-2 adrenergic receptors in the human eye","volume":"24","author":"Matsuo","year":"1992","journal-title":"Ophthalmic Res"},{"issue":"1","key":"10.1016\/j.ajo.2010.09.026_bib51","first-page":"65","article-title":"Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration","volume":"40","author":"Yoles","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ajo.2010.09.026_bib52","first-page":"2849","article-title":"Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension","volume":"42","author":"WoldeMussie","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2010.09.026_bib53","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.exer.2008.02.008","article-title":"Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments","volume":"86","author":"Hern\u00e1ndez","year":"2008","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.ajo.2010.09.026_bib54","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archopht.120.6.797","article-title":"Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells","volume":"120","author":"Gao","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2010.09.026_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S0952523802191152","article-title":"Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat","volume":"19","author":"Lai","year":"2002","journal-title":"Vis Neurosci"},{"issue":"10","key":"10.1016\/j.ajo.2010.09.026_bib56","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1167\/iovs.08-2078","article-title":"Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity","volume":"49","author":"Dong","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2010.09.026_bib57","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","article-title":"Preclinical evaluation of brimonidine","volume":"41","author":"Burke","year":"1996","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2010.09.026_bib58","first-page":"547","article-title":"Role of alpha-2 agonists in neuroprotection","volume":"48","author":"Wheeler","year":"2003","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2010.09.026_bib59","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0161-6420(00)00654-0","article-title":"Vitreous concentration of topically applied brimonidine tartrate 0.2%","volume":"108","author":"Kent","year":"2001","journal-title":"Ophthalmology"}],"updated-by":[{"DOI":"10.1016\/j.ajo.2011.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000}}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939410007713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939410007713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T19:11:55Z","timestamp":1674587515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939410007713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0002939410007713"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2010.09.026","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.719877077.793500542","asserted-by":"object"}]},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2010.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}